Follow-up practices for high-grade extremity Osteosarcoma

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Rothermundt, Christian ^a   Seddon, Beatrice M ^b   Dileo, Palma ^b   Strauss, Sandra J ^b   Coleman, Joanne ^c   Briggs, Timothy W ^c   Haile, Sarah R ^d   Whelan, Jeremy S ^b  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Follow up; Imaging; Osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHILD; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MEGADOSE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OVERALL SURVIVAL; PLEURA EFFUSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SECONDARY; TUMOR RECURRENCE; X RAY; X-RAY COMPUTED TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; X-RAYS;

EID: 84965010163     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2333-y     Document Type: Article

References (27)

1. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer (Oxford, England: 1990). 2013;49(3):684-95.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531-43.
3. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559-68.
4. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. Cancer. 2013;119(14):2645-53.
5. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii113-123.
6. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professional/physician_gls/pdf/bone.pdf.
7. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii100-9.
8. Puri A, Gulia A, Hawaldar R, Ranganathan P, Badwe RA. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res. 2014;472(5):1568-75.
9. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-84.
10. Mettler Jr FA, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248(1):254-63.
11. Authority HR. Definig research - National Research Ethics Service guidance to help you decide if your project requires review by a Research Ethics Committee. In.; rev. April 2013. http://www.hra-decisiontools.org.uk
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81.
13. Therneau TM. A package for survival analysis in S, R package version 2.37-7. 2014.
14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
15. CORE TEAM R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
16. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004-11.
17. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR, Eckardt JJ. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12(9):1849-58.
18. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Prever AB, Fagioli F, Comandone A, Bacci G. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003;21(4):710-5.
19. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2005;104(10):2214-21.
20. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, Versari M, Picci P. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta oncologica (Stockholm, Sweden). 2005;44(7):748-55.
21. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-90.
22. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Bohling T. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407-14.
23. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Papai Z, Meyer J. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279-87.
24. Marina S, Smeland S, Bielack S, Bernstein M, Jovic G, Hook JM, Krailo M, Butterfass-Bahloul T, Kühne T, Eriksson M. MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1 CTOS 2014, Paper 032. 2014.
25. Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014;110(10):2420-6.
26. Blunn GW, Briggs TW, Cannon SR, Walker PS, Unwin PS, Culligan S, Cobb JP. Cementless fixation for primary segmental bone tumor endoprostheses. Clin Orthop Relat Res. 2000;372:223-30.
27. Yasko AW. Surgical management of primary osteosarcoma. Cancer Treat Res. 2009;152:125-45.